In the bustling, high-stakes environment of Mbarara’s red-light district, Lisa Mutoni navigates a daily reality defined by survival. For sex workers in this western Ugandan city, the threat of HIV is an omnipresent shadow. While Mutoni is diligent about using condoms, she frequently encounters clients who insist on removing or tearing them, leaving her vulnerable. To manage this risk, she relies on pre-exposure prophylaxis (PrEP), traditionally administered as a daily pill.
However, a revolutionary medical breakthrough exists: lenacapavir, a long-acting injection that provides near-total protection against HIV with just two doses a year. For women like Mutoni, this is more than just medicine; it is a life-altering liberation from the stigma and the logistical burden of daily medication. Yet, despite the scientific triumph of the drug, a chasm remains between the laboratory and the bedside. In Mbarara and across the developing world, the promise of "lena" is currently eclipsed by a frustrating, dangerous reality: it is nowhere to be found.
The Science of Hope: Why Lenacapavir Matters
Developed by Gilead Sciences, lenacapavir has been hailed by the global health community as a potential "game changer." Unlike oral PrEP, which requires strict adherence—a significant barrier for individuals facing poverty, social instability, or the fear of domestic violence—lenacapavir offers a six-month window of immunity.
For transient populations, such as migrant workers or sex workers who may relocate for months at a time, the injection offers a "set it and forget it" solution. "If you know that you have that injection for six months, you feel like you are safe," Mutoni explains. "And it is very good, nice, because sometimes you can also forget. If it is the pill, you can forget to swallow."
The clinical potential of the drug extends beyond individual protection. Public health experts argue that by providing long-lasting, reliable immunity, the drug could theoretically halt the transmission chains that fuel the HIV epidemic, potentially driving down infection rates on a global scale.
A Chronology of the Crisis and the Recent Shift
The journey of lenacapavir from a clinical success to a public health commodity has been fraught with logistical bottlenecks and ethical debates.
- Early 2024: High-level clinical trials validate the efficacy of lenacapavir, showing near-perfect prevention rates in diverse cohorts.
- April 2025: Local health centers in Mbarara receive their first, meager shipments—a mere 40 doses—with strict mandates to prioritize only pregnant mothers.
- June 2025: A second shipment of 70 doses arrives at the Mbarara Health Centre IV, only to be exhausted within ten days, leaving hundreds of high-risk individuals on waiting lists.
- February 2026: Rollouts begin in select nations like Zimbabwe, highlighting the disparity between countries that have secured supply chains and those, like Uganda, that are struggling with intermittent access.
- Late 2026: The U.S. Food and Drug Administration (FDA) grants tentative approval to a generic version of the drug, marking a potential turning point for equitable global distribution.
Supporting Data: The Disparity in Access
The statistics surrounding the HIV epidemic in Mbarara are stark. The city’s adult HIV prevalence is estimated at 10%—double the national average for Uganda. This elevated rate is driven largely by the city’s role as a hub for transactional sex.
The economic disparity regarding the drug is perhaps the most contentious element of the current landscape. In the United States, the list price for lenacapavir is $28,218 per year. Conversely, the newly approved generic version is expected to be available to 120 low-income countries at a cost of roughly $40 annually.
Despite this price reduction, the volume of production remains the primary failure. Andrew Hill, a senior visiting research fellow at the University of Liverpool and an expert in HIV treatment, warns that current rollout speeds are insufficient. "The rate of growth isn’t fast enough," Hill stated. "We need to be getting to the millions pretty soon." The Global Fund has set a target of reaching 3 million people by the end of 2028, but critics argue that without a massive acceleration in manufacturing, this goal remains purely aspirational.
Official Responses and Corporate Accountability
The role of Gilead Sciences has come under intense scrutiny from international aid organizations. Doctors Without Borders (MSF) has been particularly vocal, accusing the pharmaceutical giant of prioritizing profit margins over humanitarian necessity.
"Gilead says it wants to end the HIV epidemic ‘for everyone, everywhere,’ but its actions say otherwise," said Melissa Barber, an MSF USA global health advocacy and policy adviser. MSF is currently calling on Gilead to allow for broader access to generic licensing and to facilitate direct sales to aid groups, which would allow for faster, more efficient distribution in the field.
While Gilead has entered into voluntary licensing agreements to allow generic production, advocates argue these agreements are often too restrictive, limiting the number of manufacturers and keeping supply levels artificially low. The tension between intellectual property rights and the "right to health" remains the central debate in the rollout of lenacapavir.
Implications for Public Health
The failure to scale lenacapavir in regions like Mbarara has profound human and social implications. For individuals like Julius Bampe, a builder whose wife recently tested positive for HIV, the lack of access is a personal tragedy. After his wife was placed on antiretroviral therapy to suppress her viral load, Bampe sought the injection for himself as a preventative measure, only to be turned away by a system with no stock.
"When I got here, they said that is what they would have given me, but they said they didn’t have enough doses for everyone," Bampe reported. This scenario is playing out in clinics across the continent, where healthcare providers are forced to play the role of gatekeepers, deciding who receives a life-saving injection and who must settle for the "inferior" alternative of daily pills.
Immaculate Nyamwija, founder of Action for Improved Health and Wealth, which provides support to vulnerable women in Mbarara, emphasizes the exhaustion of the community. "It is a challenge, because the demand is high and the doses are few," Nyamwija notes. "Who would not wish to take (lenacapavir) for six months? Who would wish to be on drugs every day?"
Conclusion: The Road Ahead
The tentative approval of the generic version of lenacapavir by the FDA is a historic step forward, offering a pathway to bring the drug to the millions who need it most. However, the path from "tentative approval" to "in the arm" is long and complex. It requires not only the expansion of manufacturing capacity but also the strengthening of local healthcare infrastructure to handle the storage, administration, and monitoring required for the injection.
The HIV epidemic is a test of global solidarity. As the world watches the rollout of this revolutionary drug, the lesson from Mbarara is clear: scientific innovation is only as effective as the distribution systems that support it. Without a drastic increase in the supply of lenacapavir and a commitment to equitable pricing and distribution, the "lena" gap will remain a persistent, tragic barrier to the goal of ending the HIV epidemic. Until then, women like Lisa Mutoni must continue to navigate their risks with limited tools, waiting for a promise that remains, for now, largely unfulfilled.
